meta_pixel
Tapesearch Logo
Log in
WSJ Tech News Briefing

TNB Tech Minute: EU Plans to Impose Interim Measures in WhatsApp AI Probe

WSJ Tech News Briefing

The Wall Street Journal

Tech News, News

4.31.7K Ratings

🗓️ 9 February 2026

⏱️ 3 minutes

🧾️ Download transcript

Summary

Plus: Eli Lilly to buy biotech Orna Therapeutics for up to $2.4 billion. And STMicroelectronics secures a multiyear, multibillion-dollar deal with Amazon. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

How are the U.S. businesses of Philip Morris International invested in America?

0:05.0

We're invested in advancing science, giving adults who smoke better options.

0:10.0

We're invested in American manufacturing, helping local economies thrive.

0:15.0

We're invested in community, supporting military veterans and their families,

0:19.0

disaster relief, and economic empowerment.

0:22.5

Because we're proud to be invested in America.

0:25.9

See how at uspMI.com.

0:31.2

Here's your morning T&B Tech Minute for Monday, February 9th.

0:35.5

I'm Julie Chang for the Wall Street Journal.

0:39.6

The EU has sent a statement of objections to meta today as part of its investigation into its treatment of rival AI

0:45.2

chatbots on WhatsApp. The EU plans to impose interim measures requiring meta to grant

0:50.6

competing chatbots access to WhatsApp's business communication tool.

0:55.2

Meta implemented a policy in January that prevented other chatbots from tapping into the tool,

1:00.2

which the EU argued may abuse meta's dominant position.

1:03.8

A meta spokesperson said the EU wrongly assumes WhatsApp's business programming interface

1:08.7

is a key distribution channel for chatbots.

1:11.5

META can formally respond to EU's objections and injunction proposal and can request a hearing.

1:17.9

Eli Lilly is acquiring Genetic Medicine Biotech Orna Therapeutics for up to $2.4 billion.

1:24.9

Orna engineers immune cells in vivo, developing a new class of therapeutics using

1:29.7

circular RNA and lipid nanoparticles. This allows the patient's body to generate cell therapies

1:35.9

for disease treatment. Lilly sees the acquisition as a platform for long-term innovation in

1:41.4

genetic medicine and in vivo cell engineering.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from The Wall Street Journal, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Wall Street Journal and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.